胰岛素类似物治疗糖尿病脑卒中的疗效观察

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (4): 449-451.

胰岛素类似物治疗糖尿病脑卒中的疗效观察

于萍¹, 李强¹, 杨春晓², 孙玉倩¹, 梁庆成², 张巾超¹

¹哈尔滨医科大学附属第二医院内分泌科,²神经内科,哈尔滨150086,黑龙江

收稿日期:2007-12-27 修回日期:2008-03-26 出版日期:2008-04-26 发布日期:2020-10-12
通讯作者: 李强,男,博士生导师,研究方向:胰岛素强化治疗,脂肪组织的内分泌功能。Tel:0451-86605163 E-mail:hrblq@yahoo.com.cn
作者简介:于萍,女,博士,主治医师,研究方向:胰岛素强化治疗,内皮祖细胞移植。Tel:13304805562 E-mail:yuping0122@16.com

Effect of glargine combined aspart insulin when stroke happened in type 2 diabetes

YU Ping, LI Qiang, YANG Chun-xiao, SUN Yu-qian, LIANG Qing-cheng, ZHANG Jin-chao

Department of Endocrinology and Metabolism, Seond Hospial Affiliated to Harbin Medical Universiy, Habin 150086,Heilongjiang,China

Received:2007-12-27 Revised:2008-03-26 Online:2008-04-26 Published:2020-10-12

摘要/Abstract

摘要： 目的: 观察在糖尿病患者脑卒中时联合使用胰岛素类似物(甘精胰岛素联合门冬胰岛素)降糖的疗效。方法: 住院患者40例,随机分为两组。A组:餐前门冬胰岛素(诺和锐)联合睡前甘精胰岛素(来得时)降糖治疗;B组:餐前生物合成人胰岛素(诺和灵R)联合睡前精蛋白生物合成人胰岛素(诺和灵N)降糖治疗。治疗7d后, 比较两组空腹、餐后血糖以及低血糖发生次数的差别。结果: A组与B组胰岛素用量无统计学差别,但空腹血糖与餐后血糖A组均显著低于B组(空腹为7.2±0.8 vs 9.4±1.9, P<0.05;早餐后为9.0±1.8 vs 10.3±2.3, P<0.05, mmol/L),且未见低血糖发生。结论: 胰岛素类似物联合降糖能更有效控制血糖,预防低血糖发生。

关键词: 糖尿病, 脑卒中, 甘精胰岛素, 门冬胰岛素

Abstract: AIM: To explored the combination of glargine and aspart in stoke of diabetes. METHODS: 40 patients were randomly assigned to two groups for insulin therapy, glargine combined aspart group (Agroup); three regular and one NPH( B group) group. Blood glucose was detected 7 times each day. RESULTS: Fasting and post meal blood glucose were more better in A group than B group after 7 days, and less hypoglycemia happened. ( Fasting 7.2±0.8, 9.4±1.9, PK 0.05; post meal, 9.0±1.8, 10.3±2.3,P<0.05, mmol/L). CONCLUSION: Glargine combined aspart w as more effective and has less hypoglycemia in diabetes when stroke happened.

Key words: diabetes, stroke, glargine, aspart

中图分类号:

R587.1

于萍, 李强, 杨春晓, 孙玉倩, 梁庆成, 张巾超. 胰岛素类似物治疗糖尿病脑卒中的疗效观察[J]. 中国临床药理学与治疗学, 2008, 13(4): 449-451.

YU Ping, LI Qiang, YANG Chun-xiao, SUN Yu-qian, LIANG Qing-cheng, ZHANG Jin-chao. Effect of glargine combined aspart insulin when stroke happened in type 2 diabetes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(4): 449-451.

参考文献

[1] Monnier L,Lapinsbi H,Coletle C,et al. Contributions of fasting and post prandial pl asma glucose increments to the overall diurnal byperglycemia of type 2 diabetic patients:variations w ith increasing levels of HbA(1c)[J].Diabetes Care,2003,26(3):881-885.
[2] 钱荣立.关于糖尿病的新诊断标准与分型[J].中国糖尿病杂志,2000,8(1):5-6.
[3] Genich JE. Insulin glargi ne:long-acting basal insulin analog for improved metabolic contol[J].Curr Med Opin,2004,20(1):31-37.
[4] Manini R,Forlani G,Moscatielo S,et al. Insulin glarg ne improves glycemic cont rol and healthrel ated quality of life in type 1 diabetes[J]. Nutr Metab Cardiovasc Dis,2007,17(7):493-498.
[5] Bi YF,Zhao LB,li XY,et al. A 2-way cross over,openr labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients[J]. Chin Med J (Engl),2007,120(19):1700-1703.
[6] Petitt DJ,Ospina P,Howard C,et al. Eficacy,safety and lack of immunogenicity of insuli n aspart compared with regular human insulin for women with gestational diabetes mellitus[J]. Diabet Med,2007,24(10):1129-1135.
[7] Gag SK,Gottied PA,Hisatomi ME,et al. Improved glycemic control without an increase in severe hypoglyoemic epi sodes in intensively treated patients with type 1 diabetes receiving morning evening or split dose insulin glargine[J]. Diabetes Res Clin Pact,2004,66(1):49-56.
[8] Triplitt C,Glass L,Miyazaki Y,et al. Comparison of glargi ne insulin versus rosiglitazone ad tion in poorly controlled type 2 diabetic patients on metfomin plus sulfonylurea[J].Diabetes Care,2006,29(11):2371-2377.
[9] Janka HU,Plewe G,Riddle MC,et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes[J].Diabetes Care,2005,28(2):254-259.
[10] Raskin P,Allen E,Hollander P,et al. Initiat ing insulin therapy in type 2 Diabetes:a companison of biphasic and basal insulin analogs[J].Diabetes Care,2005,28(2):260-265.
[11] Braendle M. Cost effecti veness analysis of insulin glargine compared with NPH insulin based on a 10 year simulation of long tem complications with the di abetes mellitus model in patients with type 2 diabetes in Switzerland[J].Di abetologa,2004,47(Suppll):Abs957.

[1]	马言, 田高鹏, 石兴文, 孙婷, 谢晶晶, 甄东户. 探讨T2DM人群中25（OH）D与代谢相关性脂肪肝的相关性[J]. 中国临床药理学与治疗学, 2023, 28(9): 1018-1026.
[2]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[3]	马仙康, 杨丽霞, 崔阳阳, 米登海. 当归多糖通过抑制GRP78、p-PERK、p-Eif2α表达改善糖尿病KK-Ay小鼠肝内质网应激[J]. 中国临床药理学与治疗学, 2023, 28(8): 926-936.
[4]	王坤, 许佩佩, 周兰兰, 鲁晟. 人参皂苷Rg1调控Epac1/Rap1信号通路对缺血性脑卒中大鼠神经保护作用机制研究[J]. 中国临床药理学与治疗学, 2023, 28(7): 721-727.
[5]	李坤, 李璐璐, 李楠楠, 胡卫红, 周建超. 成人肾移植术后血糖控制和CYP3A5基因多态性对他克莫司谷浓度的影响[J]. 中国临床药理学与治疗学, 2023, 28(7): 767-774.
[6]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[7]	秦文秀, 许军峰, 杨婷, 王坪霏. 丹参酮IIA治疗缺血性脑卒中后神经损伤的信号通路研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 705-713.
[8]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[9]	张雪娇, 刘洁婷, 李鲁新, 陈培剑, 丁明璐, 孙梦伟, 初彦辉, 张珍. 达格列净对1型糖尿病小鼠心肌损伤的影响及机制研究[J]. 中国临床药理学与治疗学, 2023, 28(3): 257-265.
[10]	白佳, 杨虹, 李玲玲, 张洋洋, 杨莹, 吕海宏. 维生素D通过线粒体/自噬途径影响糖尿病神经病变机制的研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 214-219.
[11]	赵世峰, 宋向明, 姚建平. 新型胰高血糖素样肽-1受体/葡萄糖依赖性促胰岛素多肽受体双重激动剂——Tirzepatide[J]. 中国临床药理学与治疗学, 2023, 28(2): 220-227.
[12]	杜小雨, 李宇蒙, 吴惠珍, 邱博. 多格列艾汀治疗2型糖尿病的药理作用和临床评价[J]. 中国临床药理学与治疗学, 2023, 28(10): 1177-1183.
[13]	蔡静, 潘斌晶, 刘靖芳. 降糖药物与肌肉减少症关系的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 101-108.
[14]	杨丽, 柏虎虎, 贺沙沙, 金月, 刘成松. TRPM3的酪氨酸磷酸化参与糖尿病诱发的热痛觉过敏[J]. 中国临床药理学与治疗学, 2022, 27(9): 971-976.
[15]	翟葳葳, 余巧玲, 刘平, 邱博, 吴惠珍. 非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1067-1074.